NewsRoom Articles - Page 3 of 237

WednesdayMay 13, 2026 9:00 am

CNS Drug Delivery Technologies Are Reshaping Alzheimer’s and Biodefense Research

BioMedWire Editorial Coverage: Among the most guarded structures in human biology, the brain is also one of the hardest to treat. The blood-brain barrier (“BBB”), a specialized biological membrane, shields neural tissue from foreign substances, including most therapeutic agents. As cases of Alzheimer's disease climb worldwide and governments sharpen their focus on biodefense, the absence of efficient pathways for delivering drugs to the brain is fast becoming one of medicine's most pressing unresolved problems. Companies such as Oncotelic Therapeutics Inc. (OTCQB: OTLC) (Profile) are responding to this challenge with next-generation delivery platforms engineered to circumvent biological barriers and ensure direct,…

WednesdayMay 13, 2026 9:00 am

Next-Generation GLP-1 Innovation Could Unlock Massive Metabolic Healthcare Market Opportunities

BioMedWire Editorial Coverage: Obesity and type 2 diabetes mellitus (“T2DM”) rank among the most urgent and costly healthcare problems facing the world today, contributing to surging rates of cardiovascular disease, fatty liver disease, kidney complications and ballooning healthcare expenses. What once represented a specialized class of diabetes treatments has grown into one of the most consequential therapeutic categories in modern medicine, with GLP-1 receptor agonists now fundamentally restructuring how obesity, metabolic disease and potentially even neurodegeneration are treated. Operating in this environment is SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) (Profile), which through its subsidiary GlucaPharm Inc. is developing a…

TuesdayMay 12, 2026 10:00 am

NHS Starts Offering Immunotherapy Injection to Cancer Patients

The NHS in England is rolling out a treatment upgrade under which thousands of patients with cancer will now receive a one-minute injection of the immunotherapy pembrolizumab instead of having the drug administered via infusion as has been the case in the past. The jab slashes the administration time from hours to just a minute or two. Approximately 14,000 new cancer patients are enrolled on pembrolizumab immunotherapy infusions each year in England, and the majority of this patient population is expected to switch to the injectable form of the treatment. The drug is used in the treatment of 14 types of cancer, such as head and neck, lung, cervical and…

TuesdayMay 12, 2026 9:00 am

SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) Is ‘One to Watch’

Disseminated on behalf of SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) and may include a paid advertisement. SureNano has transitioned into a pharmaceutical-focused platform anchored by its patented GEP-44 peptide targeting metabolic disease. Preclinical data for GEP-44 demonstrates meaningful weight loss, improved glucose control, and a favorable tolerability profile relative to existing GLP-1 therapies. The company’s vertically integrated model combines therapeutic development with delivery technologies, supporting differentiation through potential non-injectable formats. SureNano is advancing GEP-44 through a defined regulatory pathway, including IND-enabling studies and planned clinical trials. The company provides exposure to the expanding GLP-1 and obesity treatment markets, which…

MondayMay 11, 2026 11:15 am

SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) Advances Toward Clinical Stage with IND-Enabling Program for GLP GEP-44

Disseminated on behalf of SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) and may include a paid advertisement. SureNano Science initiated an FDA-aligned IND-enabling GLP toxicology and pharmacology program for lead candidate GEP-44, a multi-receptor peptide targeting obesity and type 2 diabetes, positioned within the growing GLP-1 therapeutic market as a minnow among giants. The studies will assess safety, dosing thresholds, and pharmacological effects across multiple species, GEP-44 preclinical results position it head-to-head with leaders such as Ozempic, Mounjaro, Wegovy. The program is expected to support a Phase I clinical trial in Australia, subject to regulatory submission and study outcomes. The company is…

MondayMay 11, 2026 10:30 am

The Partnership Playbook: Oncotelic Therapeutics Inc. (OTLC) Advancing Its Pipeline Without Dilution

The GMP Bio joint venture contributed a $249 million increase to Oncotelic’s balance sheet through independent third-party valuation The company is leveraging a deep intellectual property portfolio, including more than 500 patent applications and 75 issued patents Oncotelic’s PDAOAI platform has integrated approximately 28 million scientific abstracts and is advancing toward commercial deployment with robotics integration In clinical-stage biotechnology, the central challenge is rarely scientific discovery. It is capital. Advancing multiple therapeutic candidates through preclinical work, clinical trials, and regulatory approval requires sustained funding, and traditional financing routes often come at the cost of dilution or loss of asset control.…

MondayMay 11, 2026 9:00 am

CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities

BioMedWire Editorial Coverage: The human brain remains one of the most protected, and difficult to treat, organs in the body. At the center of this challenge is the blood-brain barrier (BBB), a biological defense system that prevents most therapeutics from reaching the central nervous system (“CNS”). As Alzheimer’s disease cases rise globally and governments intensify focus on biodefense preparedness, the inability to deliver drugs effectively to the brain is emerging as a critical bottleneck in modern medicine. With this in mind, innovative companies, including Oncotelic Therapeutics Inc. (OTCQB: OTLC) (Profile), are working within a broader industry shift toward advanced delivery platforms designed to…

MondayMay 11, 2026 9:00 am

The Next Generation of the GLP-1 Revolution Is Already Underway

BioMedWire Editorial Coverage: Obesity and type 2 diabetes mellitus (“T2DM”) have become two of the most pressing healthcare challenges worldwide, driving rising rates of cardiovascular disease, fatty liver disease, kidney complications and escalating healthcare costs. What began as a niche class of diabetes medications has evolved into one of the most transformative therapeutic categories in modern medicine, with GLP-1 receptor agonists now reshaping obesity treatment, metabolic care and potentially even neurodegenerative disease management. Against this backdrop, SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF), (Profile) through its subsidiary GlucaPharm Inc., is advancing a differentiated next-generation GLP-1 platform centered on GEP-44, a novel…

MondayMay 11, 2026 9:00 am

The Future of Intoxication Detection May Be in Your Voice

BioMedWire Editorial Coverage: The ability to accurately detect drug and alcohol intoxication has long been a persistent challenge across industries, from law enforcement and workplace safety to healthcare and public health management. Traditional methods such as breathalyzers, blood tests and urine screenings are often limited by their invasiveness, delayed results or inability to assess real-time impairment, particularly in cases involving multiple substances. As patterns of substance use evolve and the societal costs of impaired behavior continue to rise, the demand for faster, more scalable and noninvasive diagnostic solutions is becoming increasingly urgent. MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) (Profile) is…

FridayMay 08, 2026 10:00 am

DOJ Announces Task Force to Combat Tech-Driven Fraud in Health Care

Last week, the U.S. Department of Justice announced a plan to tackle tech-driven fraud in the health care system on the West Coast. The initiative will focus on California, Arizona and Nevada. Their investigations will target fraudulent schemes, especially those executed by digital health firms. The effort will be led by the National Fraud Enforcement Division in collaboration with the offices of the attorneys general in California, Arizona and Nevada. Together, they will form a unit dubbed West Coast Health Care Strike Force. This particular initiative builds on the nationwide enforcement model through which technology firms, individuals and health care providers have been prosecuted and convicted on charges related to defrauding…